Protagenic Therapeutics Inc(PTIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PTIX Protagenic Therapeutics Inc

Pre-Mkt 12-16 04:30:17 EST

1.57

-0.08

-4.85%

High1.63	Low1.53	Vol43.35K
Open1.62	D1 Closing1.65	Amplitude6.05%
Mkt Cap3.04M	Tradable Cap3.01M	Total Shares1.93M
T/O69.01K	T/O Rate2.26%	Tradable Shares1.91M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PTIX","market":"US","secType":"STK","nameCN":"Protagenic Therapeutics Inc","latestPrice":1.57,"timestamp":1765832400000,"preClose":1.65,"halted":0,"volume":43346,"delay":0,"floatShares":1914900,"shares":1934878,"eps":-13.050695,"marketStatus":"Pre-Mkt","change":-0.08,"latestTime":"12-16 04:30:17 EST","open":1.62,"high":1.6299,"low":1.53,"amount":69006.030099,"amplitude":0.060545,"askPrice":1.93,"askSize":100,"bidPrice":1.38,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-13.050695,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1765895400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":1.57,"postHourTrading":{"tag":"盘后","latestPrice":1.57,"preClose":1.57,"latestTime":"19:58 EST","volume":1302,"amount":2039.68,"timestamp":1765846711213},"volumeRatio":0.2162892026158833},"requestUrl":"/m/hq/s/PTIX/wiki","defaultTab":"wiki","newsList":[{"id":"2590134146","title":"Protagenic Therapeutics Reports Positive Phase 1 Results for PT00114 in Stress-Related Psychiatric Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2590134146","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590134146?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:46","pubTimestamp":1765287984,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has announced positive topline safety results from its Phase 1 Multiple Dose study of PT00114, a synthetic analogue of a naturally occurring brain peptide aimed at treating stress-related neuropsychiatric conditions. The Phase 1 study, conducted in healthy volunteers, evaluated the safety, tolerability, and pharmacokinetic profile of PT00114 across multiple dose levels. No serious adverse events were observed, and reported adverse events were consistent with expectations for a peptide-based injectable therapy, including expected injection-site reactions. All participants completed the assigned dosing schedules. Protagenic Therapeutics is finalizing a comprehensive analysis of the Phase 1 dataset and plans to initiate a Phase 2 study in early 2026 to further evaluate PT00114 in patients with chronic stress-related psychiatric disorders. Detailed results and study design information for the next phase will be communicated in the coming months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8V71nz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2589081008","title":"Protagenic Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2589081008","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589081008?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:53","pubTimestamp":1764971620,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has announced that it will hold its annual meeting of stockholders on December 31, 2025. The meeting will be conducted as a virtual event via live webcast.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL79jJWV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2586181738","title":"Sector Update: Health Care Stocks Mixed Premarket Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2586181738","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586181738?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:20","pubTimestamp":1764339612,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Friday, with the Health Care Select Sector SPDR Fund (XLV) slightly lower and the iShares Biotechnology ETF (IBB) up 0.3%.Biogen (BIIB) and Eisai said a new dru","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","IE00B19Z9P08.USD","LU0109394709.USD","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4585","LU0234570918.USD","BK4581","PTIX","IBB","VNDA","LU0889565916.HKD","BIIB","BK4533","BK4532","XBI","XLV","BK4139","BK4588","LABU"],"gpt_icon":0},{"id":"2586202036","title":"Protagenic Therapeutics Faces Nasdaq Delisting Due to Compliance Issues","url":"https://stock-news.laohu8.com/highlight/detail?id=2586202036","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586202036?lang=en_us&edition=fundamental","pubTime":"2025-11-28 16:46","pubTimestamp":1764319560,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics  said Thursday it received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement and for not filing its quarterly report on time.The company said Nasdaq flagged its recently reported equity levels and the delayed Form 10-Q for the quarter ended Sept. 30, 2025. Because the company had only recently regained compliance and remains under a mandatory panel monitoring period, Nasdaq has moved to delist its shares.The company said it will request a hearing, which automatically halts any suspension for 15 days, and will also seek an additional stay while the panel reviews its case.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["QLD","USAW.SI",".IXIC","SQQQ","NQmain","USJW.SI","MNQmain","LENZ","BK4139","PSQ","TQQQ","QID","TSYW.SI","BK4007","PTIX","NVIW.SI","BK4539"],"gpt_icon":1},{"id":"2586260216","title":"Protagenic Therapeutics Delays Quarterly Financial Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2586260216","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586260216?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:19","pubTimestamp":1764191977,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has disclosed a delay in filing its Form 10-Q for the quarter ended September 30, 2025. This reporting delay was cited as one of the reasons the company received a Nasdaq non-compliance notice.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDLbYgXt5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2583000682","title":"Protagenic Therapeutics Delays Quarterly Report Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2583000682","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583000682?lang=en_us&edition=fundamental","pubTime":"2025-11-15 06:05","pubTimestamp":1763157927,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has disclosed a delay in filing its Quarterly Report on Form 10-Q for the period ended September 30, 2025. The company cited that it could not file the report by the prescribed due date without unreasonable effort or expense and expects to file within the five-day extension permitted by SEC rules.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL9t2BV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2583598723","title":"Protagenic Therapeutics Completes Dosing in Phase 1 Study of Lead Compound PT00114","url":"https://stock-news.laohu8.com/highlight/detail?id=2583598723","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583598723?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:22","pubTimestamp":1763040140,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. announced the completion of enrollment and dosing in its Phase 1 Multiple Ascending Dose  study of PT00114, a peptide-based therapeutic for stress-related neuropsychiatric and neurodegenerative disorders. The study was conducted in healthy volunteers to assess the safety and tolerability of PT00114 following multiple doses. The company previously completed a single ascending dose study earlier in 2025. Protagenic Therapeutics stated that top-line results from the MAD study are expected to be finalized and released by November 30th, and a full analysis of the safety results will be presented by the end of the month.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the ori","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL5MTWcr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2581161702","title":"Jennifer Chao Resigns from Protagenic Therapeutics Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2581161702","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581161702?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:27","pubTimestamp":1762378048,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. announced that Jennifer Chao has resigned from its Board of Directors, effective immediately. The company stated there were no disagreements between Ms. Chao and the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLwx2N8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2580115504","title":"Protagenic Therapeutics Inc: Files Complaint to Rescind Share Exchange Agreement by Which Co Acquired Phytanix Bio - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2580115504","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580115504?lang=en_us&edition=fundamental","pubTime":"2025-11-01 05:19","pubTimestamp":1761945549,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nFWN3WC34I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2578523226","title":"Protagenic Therapeutics: May Offer and Sell Shares of Common Stock of up to $1.75 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2578523226","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578523226?lang=en_us&edition=fundamental","pubTime":"2025-10-25 05:42","pubTimestamp":1761342170,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nFWN3W52LV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2578154132","title":"Protagenic Therapeutics Files Initial Beneficial Ownership Statement; Ex-CEO and Director Barrett Evans Named as 10% Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2578154132","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578154132?lang=en_us&edition=fundamental","pubTime":"2025-10-25 01:41","pubTimestamp":1761327672,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Barrett Evans as the beneficial owner, who serves as a Director, 10% Owner, and former CEO of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 24, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL7dvxct:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2561490257","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2561490257","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561490257?lang=en_us&edition=fundamental","pubTime":"2025-08-22 01:54","pubTimestamp":1755798869,"startTime":"0","endTime":"0","summary":"Aptorum Group  and DiamiR Biosciences said that DiamiR received a Clinical Laboratory Evaluation Program Test Approval for its APOE Genotyping test from the New York State Department of Health.The test identifies genetic variants associated with risk for late-onset Alzheimer's disease and other neurological conditions. The two companies expect to close their merger in Q4.Aptorum's stock more than tripled as intraday volume topped 309.7 million shares, compared with the daily average of almost 3.35 million.Protagenic Therapeutics  completed the first patient dosing in the multiple-dose portion of its Phase 1 trial of PT00114, an investigational therapy based on a brain hormone that regulates stress and emotional balance.The company expects to complete dosing by the end of August, with topline safety data anticipated by the end of September.The shares more than doubled as volume topped 147 million versus the daily average of almost 205,000.Cato  shares surged 35% after the company report","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APM","BK4139","BK4094","BK7057","CATO","APM.AU","PTIX"],"gpt_icon":0},{"id":"2561467145","title":"Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2561467145","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561467145?lang=en_us&edition=fundamental","pubTime":"2025-08-21 20:12","pubTimestamp":1755778336,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Phase 2 for Stress & Mood Disorders Set for 1Q 2026. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire  on August 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250821:nNDL4XBm4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2559396250","title":"Protagenic Therapeutics Inc. Delays Q2 Financial Report Due to Transition to Virtual Operating Model","url":"https://stock-news.laohu8.com/highlight/detail?id=2559396250","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559396250?lang=en_us&edition=fundamental","pubTime":"2025-08-15 04:57","pubTimestamp":1755205062,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025. The company cited the need to finalize accounting and disclosures related to a restructuring plan, which involves transitioning to a virtual operating model and modifying certain obligations. The delay is attributed to the effort required to ensure complete and accurate reporting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagenic Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 14, 2025, and is solely responsible for the informa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nNDLbPLNym:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX"],"gpt_icon":0},{"id":"2559898402","title":"BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2559898402","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559898402?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:57","pubTimestamp":1755122262,"startTime":"0","endTime":"0","summary":"BRIEF-Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC FilingAug 13 (Reuters) - Protagenic Therapeutics Inc PTIX.O:PROTAGENIC THERAPEUTICS INC - ON AUGUST 8 APPROVES FOCUSED RESTRU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51UE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2559982518","title":"Protagenic Therapeutics to Pause Trials, Remove CEO in Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2559982518","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559982518?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:56","pubTimestamp":1755122160,"startTime":"0","endTime":"0","summary":"Protagenic Therapeutics' board approved a restructuring plan pausing certain trials and terminating some company executives including the chief executive.The plan, which is expected to save $8 million a year, calls for the temporary suspension of expenditures and evaluating strategic alternatives for certain preclinical programs, the company said Wednesday.As part of workforce reductions, Protagenic is terminating Barrett Evans as chief executive and Colin Stott as chief operating officer. Evans and Stott remain on the board of directors.All preclinical programs originated with former Phytanix Bio have been paused. Protagenic will look for strategic alternatives, including partnerships or out-licensing, to advance those assets.The company will focus on its ongoing Phase 2 clinical trial of PT00114, which is expected to wrap up in nine months to a year.The company is also transitioning to a virtual operating model. It will eliminate certain roles associated with preclinical operations, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTIX","BK4139","BK4007","BK4539","LENZ"],"gpt_icon":0},{"id":"2559984730","title":"Protagenic Therapeutics Inc: Has Temporarily Suspended Expenditures Related to Preclinical Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2559984730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559984730?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:41","pubTimestamp":1755121263,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51UE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2559984719","title":"Protagenic Therapeutics : Terminated Employment of Barrett Evans as CEO and President and Colin Stott as Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2559984719","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559984719?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:41","pubTimestamp":1755121263,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51UE:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTIX","BK4139"],"gpt_icon":0},{"id":"2559984037","title":"Protagenic Therapeutics:All Preclinical Programs Originated With Former Phytanix Bio (Phyx-001,Phyx-002,Phyx-003,Phyx-004, Phyx-005) Have Been Paused","url":"https://stock-news.laohu8.com/highlight/detail?id=2559984037","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559984037?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:41","pubTimestamp":1755121263,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51UE:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTIX"],"gpt_icon":0},{"id":"2559898475","title":"Protagenic Therapeutics Inc: Initiated Process to Evaluate Strategic Alternatives for Those Programs, Including Partnerships and/or Out-Licensing","url":"https://stock-news.laohu8.com/highlight/detail?id=2559898475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559898475?lang=en_us&edition=fundamental","pubTime":"2025-08-14 05:41","pubTimestamp":1755121263,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nFWN3U51UE:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTIX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.protagenic.com","stockEarnings":[{"period":"1week","weight":-0.0485},{"period":"1month","weight":-0.2266},{"period":"3month","weight":-0.5382},{"period":"6month","weight":-0.5436},{"period":"1year","weight":-0.7734},{"period":"ytd","weight":-0.7711}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":0.0131},{"period":"3month","weight":0.0314},{"period":"6month","weight":0.1394},{"period":"1year","weight":0.1266},{"period":"ytd","weight":0.1615}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.425882},{"month":2,"riseRate":0.428571,"avgChangeRate":0.013845},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.030138},{"month":4,"riseRate":0.571429,"avgChangeRate":-0.073525},{"month":5,"riseRate":0.25,"avgChangeRate":-0.010364},{"month":6,"riseRate":0.25,"avgChangeRate":-0.020845},{"month":7,"riseRate":0.125,"avgChangeRate":-0.101296},{"month":8,"riseRate":0.375,"avgChangeRate":0.060413},{"month":9,"riseRate":0.25,"avgChangeRate":-0.076901},{"month":10,"riseRate":0.375,"avgChangeRate":-0.051182},{"month":11,"riseRate":0,"avgChangeRate":-0.057588},{"month":12,"riseRate":0.125,"avgChangeRate":-0.114669}],"exchange":"NASDAQ","name":"Protagenic Therapeutics Inc","nameEN":"Protagenic Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagenic Therapeutics Inc(PTIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protagenic Therapeutics Inc(PTIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protagenic Therapeutics Inc,PTIX,Protagenic Therapeutics Inc股票,Protagenic Therapeutics Inc股票老虎,Protagenic Therapeutics Inc股票老虎国际,Protagenic Therapeutics Inc行情,Protagenic Therapeutics Inc股票行情,Protagenic Therapeutics Inc股价,Protagenic Therapeutics Inc股市,Protagenic Therapeutics Inc股票价格,Protagenic Therapeutics Inc股票交易,Protagenic Therapeutics Inc股票购买,Protagenic Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagenic Therapeutics Inc(PTIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protagenic Therapeutics Inc(PTIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction